

Understanding IL-4: Outlook and Potentials

Midterm Project

Oct. 19th, 2024

Mentee: Molly Liu
Mentor: Thomas Yuan

01

Understanding
AD and Its
Market
Potentials

02


Features and
Highlights of
IL-4

03

Future Trends
and Potentials

Atopic Dermatitis is a Fast-Growing Disease With High Treatment Cost...

Symptoms



Statistics



More than **230 million** AD patients worldwide




Between 1990-2019, AD patients grew by **25%** in China



Average annual OOP for AD patients **exceeds \$600**




Risk Factors Associated With Atopic Dermatitis



Urbanization includes factors such as **air pollution** and **mental stress**. With the pace of life and urbanization rate in China continues to rise, the number of AD patients is **likely to further increase**.


...Leading to a Market With Enormous Size and Opportunities




IL-4 Biologics Have The Best Efficacy in Treating M-S AD and Many Beyond...

Trial Data			Key Observations		
					
Originator	KeyMed Biosciences	sanofi	Pfizer		
MoA	IL-4	IL-4	JAK1		AD is a chronic disease and requires long-term maintenance. The introduction of injection pens allows patients to self-administer the drug, making it more convenient to use
Dosing	Injection; 300 mg; Q2W (1 dose)	Injection; 300 mg; Q2W (1 dose)	Oral; 100 mg; Daily		
Efficacy Results (IGA 0/1)	44% ...after 16 weeks	38% ...after 16 weeks	36% ...after 12 weeks		Inclusion of Dupixent on the NRDL reimbursement list significantly reduces the OOP price for patients and improves overall patient access
Annual OOP Price (RMB)	39,816	20,020	28,470		
Approved Indications	1	5	1		Sanofi's clinical trials have identified more clinical possibilities for Dupixent in other disease areas, and the potential of IL-4 beyond AD treatment remains tremendous
Safety (FDA Warning)	No	No	Yes		

...With Many IL-4 Products on Track to Enter the Competition for M-S AD Treatment



Future of IL-4 Biologics Remains Bright For Several Reasons



Q&A